Annual Report 2023

Annual Report 2023

Loan Facility

Boan Biotech Completes Phase 3 Clinical Trial for Its Aflibercept intravitreous Injection BA9101 in China, Planning to file a BLA

Boan Biotech (6955.HK) today announced that a Phase 3 clinical trial (a comparative study of efficacy and safety) for its Aflibercept Intravitreous Injection (BA9101) in China has been completed. The ...

Voluntary Announcement Phase 3 Clinical Trial Completed in China for Aflibercept Intravitreous Injection (BA9101) and BLA to be Filed

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024

Boan Biotech Announces 2023 Financial Results

Boan Biotech (6955.HK) today announced its 2023 financial results and latest developments.High-quality development delivering remarkable performanceDuring the reporting period, the company's reven...

Annual Results Announcement for the Year Ended 31 December 2023

Notice of Board Meeting

Phase 3 Clinical Trial Completed in China for Boan Biotech’s Dulaglutide Injection BA5101. BLA to be filed soon

Yantai, March 8, 2024 – Boan Biotech (6955.HK) today announced the completion of a Phase 3 clinical trial (a comparative study of efficacy, safety, and immunogenicity) for its Dulaglutide Inject...